Inclusion Criteria

Children between ages of 4 years and 18 years.

Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC)
Definition.

Availability of a parent or guardian to provide Informed Consent.

Child is not critically ill or clinically unstable.

No CDC categories N1 and A1 (1994 revised classification for HIV infection in children
less than 13 years of age) and the CDC 1993 revised HIV classification and expanded AIDS
surveillance definition for adolescents and adults.

Non-presence of an active opportunistic infection requiring acute intervention at the time
of entry (e.g. CMV, aspergillosis, cryptococcosis, Candida, etc.). Patients receiving
treatment for an infection that requires prolonged treatment must have been stable on
therapy for at least 30 days prior to study entry.

No administration of chemotherapeutic agents, investigational agents or use of
immunomodulating agents such as IVIG, corticosteroids, interferons, pentoxifylline,
G-CSF/GM-CSF, erythropoeitin, growth hormone and other growth factors within one month of
enrollment.

None of the following laboratory abnormalities within 2 weeks of study entry:

Total WBC count less than 1500/mm(3) or an absolute neutrophil count less than 750/mm(3);

Hemoglobin less than 8.0 g/dl;

Platelet count less than 75,000/mm(3);

Creatinine greater than 2.0 x normal;

Creatinine clearance less than or equal to 50 mL/min/m(2);

Total bilirubin greater than 2 x normal;

SGOT/SGPT greater than 5 x normal;

Serum amylase pancreatic isoenzyme greater than 90 U/L (2 x upper limit of normal for
adult). Serum amylase pancreatic isoenzyme should be obtained only if total serum amylase
is greater than 180 U/L.

No history of clinical pancreatitis and/or elevation in serum amylase pancreatic isoenzyme
of greater than 180 U/L.

No history of peripheral neuropathy of Grade II or greater severity.

No previous treatment with ritonavir, indinavir, nelfinavir, nevirapine or stavudine.
Patients may have received treatment with ritonavir, indinavir, nelfinavir for less than 4
weeks.

Ability to swallow tablets.

No child for whom the volume of research blood required for study evaluation exceeds the
maximum volume of research blood allowable (3 ml/kg in a single blood withdrawal and 7
ml/kg in a 6-week period). This would be applicable to a child less than 16.5 kg.

No patients who refuse or cannot have leukapheresis done.

Sexually active post-menarchal females must be willing to use a barrier method of
contraception or be willing to remain sexually abstinent.